NASDAQ: BTAI | --- | --- | --- | --- | --- | --- | |------------|-------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | March 2020 | Next Wave of Medicines Utilizing AI | | | | | | | | | | | | | | | | | | | | | | | | | | Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, b ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2019 Earnings Conference Call March 9, 2020 8:30 AM ET Company Participants Vimal Mehta - Founder and CEO Richard Steinhart - VP and CFO Frank Yocca - SVP and Chief Scientific Officer Vincent O'Neill - SVP and Chief Medical Officer Rob Risinger - VP, Clinical Development Conference Call Participants Robyn Karnauskas - SunTrust Robinson Humphrey Sumant Kulkarni - Canaccord Genuity Do Kim - BMO Capital Markets Raghuram Selvaraju - H.C. Wainwright Operator Good morni ...

Table of Contents | --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------ ...

bioxcel therapeutics (NASDAQ: BTAI) | --- | --- | --- | |---------------------------------------------------------------------------------|-------|-------| | | | | | | | | | Next Wave of Medicines | | | | | | | | December 2019 BioXcel Therapeutics, 555 Long Wharf Drive, New Haven, CT 06511 1 | | | Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation includ ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2019 Earnings Conference Call November 14, 2019 8:30 AM ET Company Participants Vimal Mehta - Founder and Chief Executive Officer Richard Steinhart - Vice President and Chief Financial Officer Frank Yocca - Senior Vice President and Chief Scientific Officer Vincent O'Neill - Senior Vice President and Chief Medical Officer Conference Call Participants Do Kim - BMO Capital Markets Minh Vong - SunTrust Robinson Humphrey Sumant Kulkarni - Canaccord Genuity Corp. Edwar ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38410 BioXcel Therapeutics, Inc. (Exact name of registrant as specified in its Charter) Delaware 82‑13867 ...

bioxcel therapeutics (NASDAQ: BTAI) | --- | --- | --- | |------------------------|-------|-------| | | | | | | | | | Next Wave of Medicines | | | | | | | | September 2019 | | | Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, but are not limited to, statements that relate to the advancement and development of BXCL501 and BXCL701, anticipated m ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q2 2019 Results Conference Call August 6, 2019 8:30 AM ET Company Participants Vimal Mehta - CEO Richard Steinhart - CFO Frank Yocca - Chief Scientific Officer Vincent O'Neill - SVP & Chief Medical Officer Conference Call Participants Andrea Brettler - UBS Edward White - H.C. Wainwright Operator Good morning, and welcome to BioXcel Therapeutics Second Quarter 2019 Earnings Conference Call and Audio Webcast. Before we start, I would like to inform you that this confer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38410 BioXcel Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82‑1386754 (Sta ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38410 BioXcel Therapeutics, Inc (Exact Name of Registrant as Specified in its Charter) Delaware 82‑1386754 (Sta ...